| Identification | Back Directory | [Name]
DROXIDOPA | [CAS]
23651-95-8 | [Synonyms]
l-dops
SM 5688
DROXIDOPA
Droxydopa
l-threodops
Droxidopa-13C6
Droxidopa (JAN)
threo-Dopaserine
DROXIDOPA,SM 5688
L-threo-Droxidopa
Droxidopa impurity B
(βR)-β,3-Dihydroxy-L-tyrosine
3-dihydroxy-betthreo-l-tyrosin
L-threo-3,4-Dihydroxyphenylserine
L-Tyrosine, β,3-dihydroxy-, (βR)-
3-dihydroxy-bet(beta-r)-l-tyrosin
L-Tyrosine, b,3-dihydroxy-, (bR)-
L-Tyrosine, b,3-dihydroxy-, threo-
4-dihydroxyphenyl)-3-(l-threo-serin
L-threo-b-(3,4-Dihydroxyphenyl)serine
l-threo-3-(3,4-dihydroxyphenyl)serine
Serine, 3-(3,4-dihydroxyphenyl)-, L-threo-(8CI)
(2S,3R)-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic acid
(2S,3R)-3-(3,4-Dihydroxyphenyl)-2-amino-3-hydroxypropanoic acid
(2S,3R)-2-aMino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid
(-)-(2s,3r)-2-amino-3-hydroxy-3-(3,4-dihydroxyphenyl)propionicacid
(-)-(2S,3R)-2-Amino-3-hydroxy-3-(3,4-dihydroxyphenyl)propionic acid | [Molecular Formula]
C9H11NO5 | [MDL Number]
MFCD00799030 | [MOL File]
23651-95-8.mol | [Molecular Weight]
213.19 |
| Chemical Properties | Back Directory | [Melting point ]
232-235° (dec); mp 229-232° (dec) (Ohashi) | [alpha ]
D20 -39° (c = 1 in 1N aq HCl); D20 -42.0° (c = 1 in 1N aq HCl) | [Boiling point ]
549.8±50.0 °C(Predicted) | [density ]
1.608±0.06 g/cm3(Predicted) | [storage temp. ]
?20°C | [solubility ]
DMSO: ≥3mg/mL | [form ]
powder | [pka]
2.09±0.24(Predicted) | [color ]
white to tan | [Merck ]
14,3457 | [Stability:]
Hygroscopic | [InChI]
InChI=1/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/s3 | [InChIKey]
QXWYKJLNLSIPIN-WWXSATIUNA-N | [SMILES]
[C@H](C1C=CC(O)=C(O)C=1)(O)[C@H](N)C(=O)O |&1:0,10,r| | [CAS DataBase Reference]
23651-95-8 |
| Hazard Information | Back Directory | [Chemical Properties]
Off-White Solid | [Usage]
Droxidopa is a psychoactive drug and acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline). | [Usage]
The L-threo-form Droxidopa. A synthetic amino acid precursor of Norepinephrine (N674500). Antiparkinsonian. | [Definition]
ChEBI: A serine derivative that is L-serine substituted at the beta-position by a 3,4-dihydroxyphenyl group. A prodrug for noradrenalone, it is used for treatment of neurogenic orthostatic hypotension | [Description]
Droxidopa is a synthetic amino acid precursor of (-)-norepinephrine which is absorbed
from the gut and metabolized to norepinephrine. In Parkinsonian patients, droxidopa
added to existing levodopa/decarboxylase inhibitor therapy produces significant
improvements in retropulsion, dysarthria and muscular rigidity refractory to other
treatments; however, tremor was unaffected. | [Originator]
Sumitomo (Japan) | [Uses]
Droxidopa is a psychoactive drug and acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline). | [Uses]
The L-threo-form Droxidopa. A synthetic amino acid precursor of Norepinephrine (N674500). Antiparkinsonian. | [Brand name]
DOPS | [General Description]
L-DOPS, also called L-threo 3,4-Dihydroxyphenylserine or droxidopa is a catecholamine. L-DOPS has many clinical advantages and may be useful for treating norepinephrine deficiency. It is used for treating neurogenic orthostatic hypotension and improves norepinephrine levels. L-DOPS mediates reduction of amyloid plaques and could have a therapeutic potential for treating amyloid pathology. | [Biochem/physiol Actions]
L-DOPS is a norepinephrine precursor in vivo. | [storage]
Store at -20°C | [References]
[1] J BARTHOLINI. The stereoisomers of 3,4-dihydroxyphenylserine as precursors of norepinephrine.[J]. Journal of Pharmacology and Experimental Therapeutics, 1975, 193 2: 523-532.
[2] MAR COLL. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats??[J]. Hepatology, 2012, 56 5: 1849-1860. DOI: 10.1002/hep.25845
[3] HORACIO KAUFMANN Jose A P Lucy Norcliffe Kaufmann. Droxidopa in neurogenic orthostatic hypotension.[J]. Expert Review of Cardiovascular Therapy, 2015, 13 8: 875-891. DOI: 10.1586/14779072.2015.1057504 |
|
|